Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect
Heart failure with preserved ejection fraction | RCP Journals
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - ScienceDirect
PPT - CHARM Program: 3 Component trials comparing candesartan with placebo PowerPoint Presentation - ID:4521239
The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction - Visualmed
THE EMPEROR-PRESERVED TRIAL ppt.pptx
Cumulative number of hospital admissions: CHARM-Alternative (top left),... | Download Scientific Diagram
Comparison of PARAGON-HF, CHARM-P, TOPCAT trials on left ventricular... | Download Scientific Diagram
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial - ScienceDirect
Sensitivity analyses showing associations between non-eligibility and... | Download Scientific Diagram
![PDF] Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ff2a649ad2496775a497804af4658a751daade79/3-Table3-1.png "PDF] Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar")
PDF] Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Semantic Scholar
The Management of Heart Failure with Preserved Ejection Fraction
The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction - Visualmed
Cardiac Trials on X: "ARBs for HFpEF? A 2b recommendation in the latest guidelines, due in large part to hospitalization reduction in this now 20 year-old trial. CHARM-Preserved Trial, Lancet 2003 ♥️
CHARM Story: Lessons Learned About Role of Angiotensin Receptor Blockers
Non-eligibility for pivotal HFpEF/HFmrEF outcome trials and mortality in a contemporary heart failure cohort - ScienceDirect
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved | Nature Medicine
Management strategies in heart failure with preserved ejection fraction | Herz
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial - ScienceDirect
![PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/569ebf85700d1ed65585fd33c90b0480ff26f05b/3-Figure2-1.png "PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar")
PDF] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Semantic Scholar
THE EMPEROR-PRESERVED TRIAL ppt.pptx
Candesartan in Heart Failure Candesartan in Heart Failure | PDF | Heart Failure | Medical Treatments
